Last reviewed · How we verify
IM Ketamine
IM Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist administered intramuscularly that produces rapid-onset dissociative anesthesia and analgesia.
IM Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist administered intramuscularly that produces rapid-onset dissociative anesthesia and analgesia. Used for Treatment-resistant depression, Acute suicidal ideation, Acute pain management.
At a glance
| Generic name | IM Ketamine |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Ketamine blocks NMDA glutamate receptors in the central nervous system, leading to dissociation, anesthesia, and analgesia. The intramuscular formulation provides a non-intravenous route of administration for acute pain management and sedation. In psychiatric applications, ketamine's rapid effects on glutamatergic neurotransmission may contribute to fast-acting antidepressant and anti-suicidal ideation effects.
Approved indications
- Treatment-resistant depression
- Acute suicidal ideation
- Acute pain management
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Tachycardia
Key clinical trials
- Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. (PHASE2, PHASE3)
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
- Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 (PHASE2)
- Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression (PHASE2)
- Comparing Nebulized Ketamine,Nebulized Ketamine and Precedex and IM Ketamine for Analgesia in Pediatric Burn (PHASE1)
- Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder (EARLY_PHASE1)
- Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (PHASE2)
- Ketamine-assisted Therapy for Advanced GI Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM Ketamine CI brief — competitive landscape report
- IM Ketamine updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI